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Abstract: Chronic diseases are diseases of long duration and slow progression. Major NCDs (cardiovascular diseases, cancer, chronic 
respiratory diseases, diabetes, rheumatologic diseases and mental health) represent the predominant health problem of the Century. The 
prevention and control of NCDs are the priority of the World Health Organization 2008 Action Plan, the United Nations 2010 Resolution 
and the European Union 2010 Council. The novel trend for the management of NCDs is evolving towards integrative, holistic ap-
proaches. NCDs are intertwined with ageing. The European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) has 
prioritised NCDs. To tackle them in their totality in order to reduce their burden and societal impact, it is proposed that NCDs could be 
considered as a single expression of disease with different risk factors and entities. An innovative integrated health system built around 
systems medicine and strategic partnerships is proposed to combat NCDs. It includes (i) understanding the social, economic, environ-
mental, genetic determinants, molecular and cellular mechanisms underlying NCDs; (ii) primary care and practice-based interprofes-
sional collaboration; (iii) carefully phenotyped patients; (iv) development of unbiased and accurate biomarkers for co-morbidities, sever-
ity and follow up of patients; (v) socio-economic science; (vi) development of guidelines; (vii) training; and (viii) policy decisions. The 
results could be applicable to all countries and adapted to local needs, economy and health systems. This paper reviews the complexity of 
NCDs intertwined with ageing. It gives an overview of the problem and proposes two practical examples of system medicine applied 
(MeDALL) to NCD co-morbidities (MACVIA-LR).  
Keywords: Chronic disease, co-morbidities, health system, systems medicine, patient, active and healthy ageing, MeDALL, MACVIA-LR. 
INTRODUCTION 
 Chronic diseases are diseases of long duration and generally 
slow progression. They include the four major Non-Communicable 
Diseases (NCDs) listed by WHO [1]: cardiovascular disease, can-
cer, chronic respiratory diseases and diabetes, and other NCDs such 
as mental disorders and disabilities such as skeletomuscular dis-
eases [2]. As survival rates and durations have improved, chronic 
diseases also include communicable diseases such as HIV/AIDS 
and genetic disorders such as cystic fibrosis. In the present paper 
the term “chronic disease” will refer to NCDs [3 , 4-6] (Fig. 1).  
*Address correspondence to this author at the University of Montpellier 1, 
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 NCDs represent the major global health problem of the 21st 
century [3]. They are the world’s leading cause of disease burden 
and mortality [1] and are increasing [7]. NCDs are a major cause of 
poverty and hinder economic development [8, 9]. Prevention and 
management of NCDs are prioritised at the EU and UN levels. 
 NCDs share common risk and socio-economic factors and clus-
ter in co-morbidities. They are intertwined with ageing. 
 Poor health today is largely shaped by the NCDs. The devel-
opment of society, rich or poor, can be judged by the quality of its 
population's health, how fairly health is distributed across the social 
spectrum, and the degree of protection provided from disadvantage 
due to ill-health. Effective action against NCDs should include the 
understanding of the social and economic determinants [10]. One of 
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the earliest approaches was the intervention study carried out very 
successfully in Karelia. This project emphasized the need for theory 
based sustained activity, within a national policy framework and 
lead to an increased health expectancy, reducing in particular the 
cardiovascular and cancer risks [11, 12]. Best practice interventions 
to reduce classic coronary risk factors could eliminate most of the 
socioeconomic differences in coronary heart disease mortality [13]. 
 The challenge for NCDs in the 21st century is to deal with their 
complexity. One way is to view biology and medicine as informa-
tional sciences requiring holistic systems approaches using both 
hypothesis-driven and discovery-driven approaches. Systems medi-
cine is the application of systems biology to medical research and 
medical practice. Its objective is to integrate a variety of data at all 
relevant levels of cellular organisation with clinical and patient-
reported disease markers, using the power of computational and 
mathematical modelling, to enable the understanding of the mecha-
nisms, prognosis, diagnosis and treatment of disease [14]. Medical 
informatics will play a key role to structure, integrate and provide 
access to the enormous amount of data generated [15]. 
 Strategies for improving the care of patients with NCDs, con-
sidering the diseases in their totality with a focus on co-morbidities, 
have the potential to offer an efficient use of health service re-
sources. An innovative cost-effective health system using interac-
tions between systems medicine and integrated care should be pro-
posed to combat NCDs. It should be centred on the patient, from 
primary care to science, training and policy making. This integrated 
approach should be applicable to all countries and adapted to local 
needs, economy and health systems.  
 The present paper reviews the complexity of NCDs intertwined 
with ageing. It gives an overview of the problem from mechanisms 
to a holistic and global approach of integrated care for NCDs. Fi-
nally, it proposes two practical examples of system medicine ap-
plied to NCD co-morbidities (in the frame of the European Innova-
tion Partnership on Active and Healthy Ageing) and the understand-
ing of the mechanisms of a complex series of related diseases (IgE-
mediated allergy [16]). This paper follows and extends a previous 
one on systems medicine and integrated care for NCDs [17]. 
 There are three important areas which need to be considered to 
combat NCDs : (1) the value of addressing social determinants of 
health, a primarily political agenda; (2) improved access to primary 
care, also primarily a political agenda; and (3) the use of systems 
biology tools to evaluate elderly patients with multiple chronic 
morbidities, to seek tools that help guide therapy, a research 
agenda.  
1. NCDs REPRESENT THE PROTOTYPE OF COMPLEX 
DISEASES ASSOCIATED WITH GENE-ENVIRONMENT 
INTERACTIONS ACROSS THE LIFE CYCLE 
NCDs are Multi-Factorial  
 NCDs often share the same environmental risk factors (e.g. 
tobacco, nutrition, microbiome, indoor and outdoor air pollution 
and sedentary lifestyle) [1], leading to sustained local and systemic 
inflammation [18]. Socio-economic determinants are vital for the 
generation, severity and management of NCDs [19 , 20]. Even in 
the high- and middle-income countries of Europe, the possibilities 
for surviving and living a healthy life are still closely related to the 
socio-economic background of individuals and families. These are 
reflected in substantial and even increasing social inequities in 
health within countries across Europe. These health inequities are 
unfair and avoidable, as they are caused by unhealthy public poli-
cies and lifestyles.  
Biodiversity Loss Increases NCD Prevalence 
 The recent increase in immune and non-immune NCDs has 
been associated, at least in part, with biodiversity loss [21] and 
exposure to environmental risk factors (e.g. smoking, sedentarism, 
biomass fuel combustion and nutrition) [1].  
 Global health implications of biodiversity loss represent an 
international political issue closely linked with climate change. 
Health issues include dietary health and nutrition, infectious dis-
eases, NCDs, medicinal resources, social and psychological health. 
There is a vicious circle between biodiversity loss, poverty, social 
inequities and health impact [22]. 
Foetal and Early Life Events in NCDs 
 It is increasingly recognized that the in utero environment is an 
important determinant of adult NCDs including diabetes [23], CVD 
[24], asthma [25], COPD [26] or neuro-degenerative diseases [27]. 
Links with conserved foetal genes [28] and/or epigenetic mecha-
nisms [25, 29] have been proposed. The role of early life infections 
 
Fig. (1). Definition of chronic diseases. 
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in the development of chronic inflammatory diseases needs to be 
better understood [30 , 31]. The interest towards developmental 
determinants of NCDs in ageing has been reinforced during the 
Cyprus Presidency of the EU Council (2012). A better understand-
ing of these links will make it possible to propose effective primary 
prevention strategies [32].  
Nutrition, Cardiovascular Diseases and Diabetes  
 Nutrition is one of the key environmental factors determining 
health and disease. Our understanding of the underlying complexi-
ties of the metabolic responses, physiology and pathophysiology at 
a systems level is not sufficient. We urgently need a systems based 
approach to understand the influence of nutrition on NCDs and to 
identify the most suitable targets for disease prevention and modifi-
cation through dietary means.  
 Challenges for food and biodiversity loss encompass food pro-
duction, smallholder income generation, access to health care, 
harmful child care practices, and tackling the coexistence of under-
nutrition and caloric over-nutrition [3, 33]. Issues of food-
biodiversity interactions are the problems of micronutrient and 
vitamin deficiencies and coexisting obesity and related chronic and 
degenerative diseases. They constitute a formidable challenge for 
the future [34]. Recommendations towards healthy diet adoption are 
needed globally to prevent the onset and control of NCDs [35]. 
However, changing life style is a major challenge in public health 
efforts, and an interdisciplinary approach including social, behav-
ioural and communication sciences is urgently needed. 
Tobacco and Biomass Fuel Combustion 
 Other important risk factors of NCDs include inhaled risk fac-
tors such as tobacco [36, 37] and biomass fuel combustion [38]. 
These risk factors may already act in utero and in early life [39]. 
Any study in the prevention and control of NCDs should consider 
these risk factors. Translational epidemiology is key to explore the 
role of these risk factors for use in practice to guide interventions 
[40]. As for nutrition, tobacco cessation is changing lifestyle and 
requires a similar multidisciplinary approach.  
 The main challenge for NCDs in the 21st century is to under-
stand their complexity [17]. This requires an integrated systems 
medicine approach that leverages from extensively characterized 
patients, integration of clinical and biological data into NCD pheno-
types using multi-level/multi-layer datasets and the development of 
appropriate medical informatics infrastructure bridging ICT man-
agement and e-Health.  
 The current management strategy using clinical and biological 
criteria categorising each NCD separately is insufficient for the 
control of NCDs. The trend for NCD management is towards holis-
tic multi-modal integrated care, and multi-scale, multi-level systems 
approaches. Recent advances in systems biology and network 
analysis have opened new avenues to understanding the mecha-
nisms of co-morbidities of multi-factorial NCDs and their cluster-
ing [17].  
Gender Differences 
 The rapid rise in NCDs affects women’s health directly and 
impacts their socio-cultural and economic roles. The rapid rise in 
NCDs not only affects women’s health directly, but it can also se-
verely impact their role as unpaid carers and the sick [41]. In gen-
eral, women live longer with NCDs than men, although they are in 
poor health [42]. The ten leading causes of death in females have 
been estimated by WHO. In the world, ischaemic heart diseases, 
stroke and COPD are ranking among the five first causes of deaths 
in women [43]. . Diabetes [44] and hypertension are among the first 
10. These death estimates are consistent in high and middle-income 
countries and with some variation in low-income countries. Despite 
recent considerable progress, gender inequities represent a major 
dimension and challenge of NCDs and the consequences of their 
risk factors. This burden is an underappreciated cause of poverty 
and hinders the economic development of many countries. Gender 
differences exist in NCD risk factor responsiveness, co-morbidities, 
phenotypes and prognosis but they have not been integrated into the 
NCD complexity. 
Co-morbidities 
 NCDs cluster in co-morbidities [19]. Co-morbidity (multimor-
bidity) is the presence of one or more diseases in addition to a pri-
mary disease. Although NCDs are considered individually in most 
patients, many different NCDs are frequently seen in the same pa-
tient [8]). Co-morbidiy number and severity increase with age. 
NCD co-morbidities are associated with worse health outcomes, 
complex pharmacological interventions and clinical management 
strategies, and increased costs [45 , 46].  
Complexity of NCDs  
 Besides environmental factors and increased life expectancy, 
intrinsic host responses, such as local and systemic inflammation, 
immune response and remodeling [47, 48 , 49 , 50], are key aspects 
for the initiation and persistence of diseases and co-morbidities. 
The “Chronic disease complex phenotype” is the core concept of 
NCDs which represent the expression of a continuum or a common 
group of diseases with intertwined gene-environment interactions, 
and co-morbidities leading to complex phenotypes [17]. Similar and 
different pathways of local and systemic inflammation [51], bio-
energetics [52] repair, remodelling and senescence [53], among 
others, lead to individual-specific complex biological and clinical 
phenotypes [17]. Given the functional interdependencies between 
molecular components, a disease reflects complex network pertur-
bations that link molecules, cells, tissues and organs [54] (Fig. 2). 
These interactions lead to highly complex systems.  
2. ACTIVE AND HEALTHY AGEING IS CLOSELY RE-
LATED TO NCDs 
 NCDs affect all age groups but particularly old-age patients. 
Functioning and physical health declines with advancing age and/or 
NCD and co-morbidity [55]. Ageing increases the likelihood of 
NCDs and co-morbidities, thereby confounding their effects on 
health and well-being. As the general population ages, the number 
of patients with NCDs is growing. There may be gender differences 
[56]. The magnitude of the effect of NCDs on ageing is greater in 
developing countries [57]. 
 Active and Healthy Ageing (AHA) is a major societal challenge 
common to all European countries, to all populations. Ageing is 
intertwined with socioeconomic inequalities, is an under-
appreciated cause of poverty and hinder economic development, 
particular in undeserved populations and women. AHA should be 
promoted very early in life.  
 In the EU, several initiatives are responding to this challenge 
and consider NCD co-morbidities as key. European Innovation 
Partnerships (EIP) aim to enhance EU competitiveness and tackle 
societal challenges through research and innovation. They will ad-
dress weaknesses in the EU research and innovation (e.g. under-
investment, fragmentation and duplication), which considerably 
complicate the discovery or exploitation of knowledge and may 
ultimately prevent the entry of innovations into the market place 
and the health systems. 
 The pilot EIP on AHA will pursue a triple win for Europe 
(http://ec.europa.eu/research/innovation-
union/index_en.cfm?section=active-healthy-
ageing&pg=implementation-plan): 
• Enabling EU citizens to lead healthy, active and independent 
lives while ageing. 
• Improving the sustainability and efficiency of social and health 
care systems. 
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• Boosting and improving the competitiveness of the markets for 
innovative products and services, responding to the ageing 
challenge at both EU and global level, thus creating new op-
portunities for businesses and development. 
 The EIP on AHA will be deployed in 3 areas (Table 1).  
Table I. Action groups of the EIP on AHA 
• Action Group A1: Prescription and adherence action at regional 
level 
• Action Group A2: Personalised health management: Falls preven-
tion 
• Action Group A3: Prevention of functional decline and frailty 
• Action Group B3: Integrated care for chronic diseases, including 
remote monitoring at regional level 
• Action Group C2: Interoperable independent living solutions 
• Action Group D4: Age friendly buildings, cities and environ-
ments 
(https://webgate.ec.europa.eu/eipaha/actiongroup/index/what) 
 The overarching target of this partnership will be to increase the 
average healthy lifespan by two years by 2020 (measured by 
Healthy Life Years, HLY by 2 years) [58]. Other indicators will 
include unavoidable hospitalizations for NCDs in the elderly. 
3. P4 MEDICINE IN NCDs 
 Health and health care depend on a complex fabric of systems 
that are constantly interacting and shaping human health, particu-
larly in patients with NCDs. P4 medicine (predictive, preventive, 
personalised and participatory) was proposed a few years ago to 
take into account the contribution of genomics [59]. Systems biol-
ogy approaches have extended this concept to medicine in general 
[60]. P4 medicine represents by itself a revolution that extends far 
beyond what is usually covered by the term personalized medicine 
[61, 62]. P4 medicine is likely to be the foundation of global health 
in the future. The key benefits of P4 medicine, for the patient and 
for the healthcare system, include: 
 To prevent the occurrence of NCDs by implementing effective 
action at societal and individual levels: 
• To detect disease at an early stage, when it can be controlled 
effectively. 
• To stratify patients into groups, enabling the selection of opti-
mal therapy. 
• To reduce adverse drug reactions through the early assessment 
of individual drug responses. 
• To improve the selection of new biochemical targets for drug 
discovery. 
• To reduce the time, cost, and failure rate of clinical trials for 
new therapies. 
• To shift the emphasis in medicine from reaction to prevention 
and from disease to wellness. 
 Moreover, in addition, it is of importance to consider and in-
clude patients’ and populations’ preferences for interventions and 
health states.  
 However, “P4 medicine” may not transform health care or 
population health, except to the extent that it encompasses actions 
already recommended related to the social determinants of health 
and primary care services.  
4. INTEGRATED CARE MODEL FOR THE CONTROL OF 
NCDs 
 A worldwide debate on the efficiency of primary health care 
attempts to re-orientate health systems in developed and developing 
countries, optimising costs [63]. Health care is often provided using 
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a model that focuses on single diseases, advanced technology and 
specialist care, health being considered as the result of biomedical 
interventions. Primary health care provides the means of organising 
a complete range of care, from home to hospital, investing re-
sources rationally in the different levels of health. NCDs require an 
integrated care model using multidisciplinary and teamwork ap-
proaches in which primary care is on the front line in order to pro-
vide optimal care on a basis of adequate public health strategies 
[64, 65]. 
Information-Communication Technology (ICT) 
 ICT is needed in the implementation of integrated care in a 
systems medicine approach. Although home telemonitoring appears 
to be a promising approach to patient management, designers of 
ICT could consider ways to make this technology more effective as 
well as controlling possible mediating variables, and to consider 
diseases in their totality. Continuous and precise monitoring makes 
the clinical history of each patient a valuable source of comprehen-
sive information. More user-friendly and efficient ICT platforms 
are needed to understand and tackle NCDs in their totality for sev-
eral years using precise constructs which need to be validated [45, 
66]. The effectiveness of interventions to promote ICT adoption in 
healthcare settings remains uncertain [67] probably since co-
morbidities are not included in most plans.  
Shared Decision Making (SDM)  
 SDM, the process by which a healthcare choice is made jointly 
by the practitioner and the patient, is an essential objective for pa-
tient-centred care in an integrated ICT system [68]. An innovative 
patient management programme combines ICT and SDM in a 
multidisciplinary approach. Patients’ values and preferences should 
dominate decision making [69]. 
 A personalised patient education plan could be included and 
proposed to all patients that allows a clear evaluation and integra-
tion of patients’ values and preferences in the decision making 
process. Content, acceptance and effectiveness of such approaches 
in NCDs could be tested. 
 An innovative patient management programme could combine 
ICT, SDM, personalised patient education and an interaction be-
tween primary, secondary, and tertiary care levels when available 
and appropriate. However, for most patients it is hoped that primary 
care will have sufficient tools to monitor and manage most patients 
who have a controlled disease. This model will enable a perfect 
follow-up of patients.  
Optimizing Primary Care Practice on Co-Morbid Multi-
Factorial NCDs  
 In May 2009, the 62st WHO World Health Assembly recom-
mended re-orienting health systems globally to promote primary 
health care as the most cost-effective strategy [63]. Health care 
often focuses on single diseases, advanced technology, biomedical 
interventions and specialist care. Most health care takes place in 
primary care settings [70], with its emphasis on providing a com-
plete range of care, from home to hospital, and on investing re-
sources rationally. Fragmenting care can cause primary care clini-
cians to lose essential skills and reduce their ability to ensure that a 
patient’s care is comprehensive, integrated, holistic, and coordi-
nated [71]. One considerable challenge in primary care is deciding 
whether a person has a significant NCD or temporary symptoms, 
given that nearly 3 out of 4 presenting complaints are self-limited 
[72].  
Practice-based Inter-Professional Collaboration (IPC)  
 IPC interventions can improve healthcare processes and out-
comes. However, rigorous, cluster randomised studies, with an 
explicit focus on IPC and its measurement, are needed to provide 
better evidence of the impact of practice-based IPC interventions on 
professional practice and healthcare outcomes [73]. Any study 
should include qualitative methods to provide insight into how the 
interventions affect collaboration and how improved collaboration 
contributes to changes in outcomes. 
Interactions between Primary Care and Research: Community-
Based Participatory Research 
 New approaches to supplement existing methods are needed to 
take research from bench to bedside and from bedside to practice. 
Community-based participatory research is an emerging model that 
enhances ongoing clinical research by involving key stakeholders, 
including community members and patients. The missions of this 
model are: (i) to investigate questions related to NCDs; (ii) to im-
prove the quality of primary care; and (iii) to carry out the wide-
spread dissemination and adoption of new information which will 
positively impact overall health at both a local and national level. 
5. DEFINITION OF NCD PHENOTYPES 
From Individual NCDs to Complex NCDs with Co-Morbidities 
 The current management strategy using clinical and biological 
criteria categorising each NCD separately is insufficient for the 
control of NCDs. NCD definitions usually follow the international 
standards/guidelines for each disease (hypothesis-driven approach: 
classical phenotypes). The novel concept of “chronic disease com-
plex phenotypes” (discovery-driven approach: novel phenotypes) 
centred on patient (co-morbidities, risk factors, socio-economic 
determinants, gender and age) as defined in the MeDALL project 
[16] is favored by comparison to classical phenotypes based on 
disease ontologies (CAD, COPD, DM2) for a comprehensive defi-
nition of co-morbid NCD clustering of clinical usefulness (Fig. 3).  
 Classical phenotypes (CAD only, COPD only, DM2 only, 
CAD+COPD, CAD+DM2, COPD+DM2, CAD+COPD+DM2) can 
be described with respect to risk factors, socio-demographic, clini-
cal and functional characteristics. Clustering of risk factors can be 
assessed and contribute to the overlap of classical phenotypes esti-
mated. Special attention should be given to factors that may add 
complexity to NCDs clinical decision-making, such as medications, 
socioeconomic factors, health status, and other NCDs. 
 Novel phenotypes can be identified using a hypothesis-free 
approach that can allow identifying the clustering of NCDs in pa-
tient populations (cross-sectional studies or cohorts) by measuring 
the distances between variables which include those used for NCDs 
definition and severity. Several statistical models can be used: first, 
diseases will be considered as discrete entities (yes/no) using latent 
class analysis; then continuous processes for the diseases (e.g., 
glucose tolerance for diabetes, carotid intima media thickness for 
CVD, and pulmonary function for COPD) will be considered using 
cluster analysis. Several stopping rules, such as Calinski-Harabasz 
[74] or CritCF, for the number of clusters (new potential pheno-
types) can be applied and their differences (if any) be tested and 
quantified. The resulting groups should be described with respect to 
risk factors, sociodemographic, clinical and functional characteris-
tics. These new entities should then be validated for their clinical 
meaning against potential risk factors of NCDs (e.g., lifestyle, envi-
ronmental and socioeconomic risk factors) and outcomes (e.g., drug 
response) as well as follow-up using previous experiences in EU 
projects MeDALL, Synergy-COPD and Biobridge. The identifica-
tion of novel phenotypes is important for a better understanding of 
NCDs and co-morbidities and can, at present only be approached in 
research. However, in the future it can make a promessing cluster-
ing of NCDs of clinical value. 
Concepts of Disease Severity, Activity, Control and Respon-
siveness to Treatment  
• Severity: loss of function in the target(s) organs induced by 
disease [75]. It is important to highlight that severity may vary 
overtime and needs to be regularly re-evaluated, in particular 
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since the population is ageing [76]. Notably, temporal fluctua-
tions of disease markers may provide a diagnostic or pheno-
typic signal by themselves [77, 78].  
• Activity: level of biological process activation that drives 
disease progression [79]. This is a fundamental concept that 
needs to be clearly separated from “severity” because treat-
ment strategies are different. Hence, whereas treatment of dis-
ease activity aims at stopping and/or reducing the progression 
of the disease, thus eventually avoiding the occurrence of se-
vere disease, treatment of severity aims at palliating the impact 
of the disease on patient’s health status. Current management 
of NCDs focuses on treatment of severity but neglects treat-
ment of activity because of the lack of validated activity bio-
markers.  
• Control: degree to which therapy goals are currently met [76]) 
such as glycemic control in diabetes [80]. The lack of vali-
dated biomarkers of disease activity limits their use in most 
NCDs. 
• Responsiveness: ease with which control is achieved by ther-
apy [75]. Adherence to therapy is a key component of respon-
siveness and should also be monitored. 
 These concepts are linked (Fig. 4).  
 The uniform definition of severe asthma presented to WHO 
used this approach [82]. It has been proposed for allergic diseases 
(Fig. 5) and may be extended to assess the severity of NCDs (Table 
2) [83].  
6. MACVIA-LR: THE MULTIDISCIPLINARY APPROACH 
OF THE LANGUEDOC ROUSSILLON REGION ON NCD 
CO-MORBIDITIES AND AGEING  
 Most patients with chronic diseases have more than one disease. 
At 70 yrs of age most patients suffer at least from 2-3 comorbid-
ities. However, these comorbidities are not identified and, as an 
example, many elderly diabetics are hospitalized for non-diabetes  
 
 
Fig. (4). Complex interplay between severity, control, responsiveness to 
treatment and risk in asthma (from Busse et al, [81]). 
 
conditions although mostly linked to comorbidities. The detection 
of comorbidities and their management will reduce unavoidable 
hospitalizations as this has already been demonstrated for diabetes 
[84]. A similar tend is expected for other NCDs. 
 In most NCD patients a screening of comorbidities is never 
done although a large part of the morbidity, mortality, hospitaliza-
tion and resources are caused by severe comorbidities [85]. Moreo-
ver, the current NCD management is characterized by the addition 
of interventions and recommendations coming from the various 
medical specialists involved. Minimal interactions between them 
and limited information to the general practitioner lead to a frag-
mented health approach, non-concerted prescriptions, a scattered 
follow-up and a high cost-effectiveness ratio [63]. It is therefore of 
 
Fig. (3). Classical (hypothesis-driven) and novel (discovery-driven) phenotypes of NCDs (from Bousquet et al [17]). 
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paramount importance to assess major comorbidities in NCD pa-
tients using a simple multidisciplinary approach. MACVIA-LR 
(Fighting Chronic Diseases for Active and Helathy Ageing) is the 
initiative lead by the Région Languedoc Roussillon, the University 
of Montpellier 1, the teaching university hospitals of Montpellier 
and Nîmes (France) with private and public stakeholders to tackle 
NCD co-morbidities and ageing. 
 A one-day chronic disease clinic can assess if (i) major NCD 
comorbidities and their risk factors can be screened, (ii) an overall 
assessment of severity of all co-morbidities can be performed (iii) a 
risk assessment can be made in order to predict and prevent acute 
events and long-term prognosis. In this clinic, a patient is admitted 
and discharged on the same day.  
 Investigated criteria include questionnaires, physical examina-
tion, other exams and biologic tests on peripheral blood and urine. 
They were selected using a systematic approach presented in this 
paper.  
Selection of Criteria used to Develop a One-Day Chronic Dis-
ease Clinic 
 The list of criteria to be investigated in the one-day chronic 
disease clinic was evidence-based depending on the major NCD co-
morbidities. Since there was no defined list of criteria, a proposal 
was developed by methodologists and clinicians. It includes the 
criteria for (i) the screening of comorbidities of CVD, COPD or 
D2M, (ii) the prediction of their exacerbations and (iii) the overall 
appreciation of severity (Fig. 6). 
 
Fig. (5). Uniform severity of allergic diseases (from Bousquet et al [83]). 
 
Table 2. Uniform severity in asthma and type-2 diabetes. 
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1. Criteria 
a. Questionnaire on disease, comorbidities, overall severity and 
risk factors (less than 1 hr). 
b. Physical examination 
c. Biomarkers on peripheral blood and/or urine.  
d. Exams. 
2. Selection of criteria 
a. Item included in guidelines and/or recommendations. 
b. Item not included in guidelines and/or recommendations: 
i Sensitivity to screen or diagnose the chronic disease (not 
severity). 
ii Specificity to screen or diagnose the chronic disease (not 
severity). 
iii Safety and side effects. 
c. Cost. 
d. Duration. 
e. Integration in the chronic disease clinic. 
f. Patient’s views  
i Results of the item (including long-term psychological ef-
fects of a diagnosis, e.g. discovery by chest CT scan of a 
nodule). 
ii Patient’s acceptance of each individual criteria and of the 
chronic diseases clinic. 
3. Criteria considered 
 The list of criteria included in the one-day clinic has been estab-
lished using a Delphi process. It is an iterative approach to seeking 
agreement from an expert panel using a validated consensus-
development methodology that enables a group of experts to deal 
with a complex problem via a structured group communication 
process [86]. The method is based on the assumption that group 
judgments are more valid than individual judgments. It uses an 
iterative process of questioning and, after each round of questions, 
an independent facilitator provides an anonymous summary of the 
experts’ views from the previous round.  
 The current list is proposed as a common list which will be used 
for all patients referred to the clinic. However, there will be some 
age-specific criteria (frailty and falls in the elderly). In the future, it 
is possible that depending on a pre-screening the list will be based 
on patient’s characteristics before assessment in the clinic. When 
available, the recommendations of the French Authority of health 
(Haute Autorité de Santé, HAS) were used.  
Electronic Co-Morbidity Clinic Investigating COPD, Coronary 
Heart Disease (CAD) and Type 2 Diabetes (D2M) 
1. Co-morbidity screening 
 The following comorbidities are currently tested: 
• Cardiovascular. 
• Diabetes. 
• Metabolism/obesity. 
• Chronic respiratory diseasess.  
• Chronic kidney disease.  
 The list will be optimized with time depending on new evi-
dence, new technologies, integration of the different criteria in the 
one day clinic, shorten duration of any test, decreased costs….. 
2. Assessment of Risk Factors 
• Tobacco is the most common risk factor for death. 
• Diet and alcohol:  
• Physical exercise. 
• Socio-economic status 
• Outdoor air pollutants increase respiratory and CV morbidity 
[87] but will not be studied because of the length of the ques-
tionnaire. 
3. Global Assessment of a Patient with an NCD 
• Cognitive function: Cognitive impairment may increase the 
risk of cardiovascular events [88] and participate to patient’s 
literacy, an essential component of treatment adherence. 
• Depression: Depression is common in NCDs [89]. NCDs can 
increase the risk of depression which, in turn, can intensify 
 
Fig. (6). Chronic disease clinic to assess NCD co-morbidities. 
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NCD severity, impact on health service and worsen overall 
prognosis [90]. 
• Mood and anxiety: Anxiety, although as common as depres-
sion, has received less attention and is often undetected and 
undertreated. A 2-item screening test may enhance detection 
[91]. 
• Quality of life: The presence of multiple chronic conditions is 
associated with lower health related quality of life (HRQOL). 
Disease severity also influences HRQOL [92]. 
• Frailty: Functional decline is a major health problem, particu-
larly in ageing countries. The prevalence of disabilities in-
creases dramatically with age. While the great majority of eld-
erly people consider themselves to be in good health and lead 
independent lives, a significant proportion, 10-20% depending 
on the definition, would be classified as frail [93]. NCDs in-
crease frailty. The EIP on AHA has proposed a specific action 
(A3) concerning frailty [94]. 
• Adherence to treatment: Non-compliance and limited health 
literacy (user-friendly information) are major barriers to the 
benefits of evidence-based treatments [95] accompanied with 
increased health services utilisation, and expenditures.  
4. Prediction of risk (acute events or long-term outcome of indi-
vidual NCD and co-morbidities) 
• The Charlson co-morbidity index predicts the ten-year mor-
tality for a patient with a screening of 22 co-morbid conditions 
[96]. Other co-morbidity indexes include the Cumulative Ill-
ness Rating Scale (CIRS), that takes into account disease se-
verity [97], the Index of Coexisting Disease (ICED) [98] or the 
Kaplan-Feinstein Classification [99]. The Charlson Index has 
excellent reliability and the others have acceptable reliability 
[99]. 
• Falls in the elderly: Approximately 30% of people over 65 
years of age fall each year and one third of them are repeated 
fallers. Approximately 30% of falls result in an injury that re-
quires medical attention, with fractures occurring in approxi-
mately 10%. Falls are the third leading cause of years living 
with disability and are also one of the leading causes for hospi-
talization leading to high costs [100]. Falls can also have psy-
chological consequences: fear of falling and loss of confidence 
that can result in self-restricted activity levels resulting in re-
duction in physical function and social interactions. There is a 
large body of evidence on the effectiveness of fall prevention 
interventions [101-103]. The EIP on AHA has proposed a spe-
cific action (A2) concerning a fall prevention initiative [94].  
• Cardiovascular risk (including risk charts): Cardiovascular 
risk (CV) charts have been proposed for a long time. Elec-
tronic health record data can be used to automatically perform 
CVD risk stratification and identify patients in need of risk-
lowering interventions [104]. This could improve detection of 
high-risk patients of whom physicians would otherwise be un-
aware. The CV risk model based on classic risk factors (e.g. 
cholesterol, blood pressure) may be refined if it included bio-
markers (C-reactive protein, N-terminal pro-B-type natriuretic 
peptide, troponin I) [105]. 
• Respiratory risk: Many instruments including the BODE-
index (Body mass index, Obstruction, Dyspnea, Exercise ca-
pacity) [106] and the HADO-score (Health, Activity, Dyspnea, 
Obstruction) have made the prediction of mortality among 
COPD patients. Comorbidities are frequent in COPD and 12 of 
them negatively influence survival. The BODE index was 
combined with the Charlson index to obtain a co-morbditiy 
risk in COPD [107]. Some biomarkers may improve the risk 
determination in COPD [108, 109]. 
 
Integrated Care, CDSS and ICT 
 “Integrated care is a concept bringing together inputs, delivery, 
management and organization of services related to diagnosis, 
treatment, care, rehabilitation and health promotion. Integration is a 
means to improve services in relation to access, quality, user satis-
faction and efficiency” [110]. Integrated care is of importance to 
service provision to the elderly, as elderly patients often are chroni-
cally ill and present several co-morbidities. 
 Clinical Decision Support Systems CDSS (Linkcare®), an inter-
active decision support system (DSS) Computer Software specific 
to the co-morbidity clinic will assist physicians and other health 
professionals with decisions for diagnosis and management of pa-
tients. It will also be linked with the Dossier Pharmaceutique® and, 
for the CHU of Montpellier, IP-Soins® (Fig. 7). The Dossier Phar-
maceutique® (pharmaceutical dossier, article L.1111-23 Code de la 
santé publique) aims at the electronic monitoring of patient’s pre-
scriptions by the pharmacists. 15,000/22,000 pharmacists in France 
are using the system which makes it possible to follow the prescrip-
tion of medications (article L. 4211-1).  
 This integrated systems will make it possible continuity of care 
which is often subdivided in 3 components: (i) Continuity of infor-
mation (though shared records), (ii) continuity across the secon-
dary-primary care interface (discharge planning from specialist to 
primary care), (iii) provider continuity (seeing the same profes-
sional each time with value added if there is a therapeutic, trusting 
relationship).  
Public-Private Partnership 
Hospital Based Clinic and Links with Primary Care 
 The CHU of Montpellier has set up the clinic and use IP-Soins® 
as an ICT tool. Patients with NCDs (WHO 2008 [1] and DG Sanco 
2012 [111] definitions) will be referred to the chronic disease clinic 
of the hospital by a primary care physician. After co-morbidity 
evaluation, the patient will be followed up in primary care. 
Mobile Chronic Disease Clinic 
 A mobile chronic disease clinic has been set up using the same 
examinations in order to screen co-morbidities in remote areas of 
rural counties of the Region. Pilot studies will be carried out in the 
maisons médicales pluridisciplinaires by the project DeProPASS 
(Dépistage des Pathologies associées aux maladies chroniques). 
7. SYSTEMS BIOLOGY ITERATING CLINICAL AND BIO-
LOGICAL DATA 
 A biomarker, or biological marker, is an indicator of a biologi-
cal state, or the past or present existence of a particular type of or-
ganism. It is not necessarily a genomic or post-genomic one. Blood 
lipids are a risk factor for cardiovascular disease [112]. However, 
for many diseases (including chronic respiratory diseases), bio-
markers do not exist and need more sophisticated approaches. Al-
though this has not been confirmed, it is proposed in this paper that 
systems biology may help to discover new pathways for disease 
prediction, monitoring and prevention. Biomarkers of pharmacoge-
nomics will also be of interest. 
Understanding Co-Morbidities Using Network Analysis  
 Biological information on gene and environment is connected 
to NCD complex phenotypes by biological networks/circuits that 
capture, integrate and transmit information to molecular machines 
(often proteins) that perform the biological function. Network 
medicine provides a new conceptual framework using biological 
networks to describe and model disease complexity [54, 113]. Net-
work analysis can explore systematically the molecular complexity 
of NCDs, leading to the identification of disease modules and 
pathways, and the molecular relationships among apparently dis-
tinct pathophenotypes. Potential novel genes are those that interact 
with the largest number of known disease genes, and such a prop-
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erty suggests a high likelihood that the gene belongs to the disease 
cluster [113]. Furthermore, the susceptible candidate genes could be 
implicated in several disease modules suggesting that different 
disease modules can overlap [54]. Comorbidity of chronic diseases 
has been studied [114] and significant correlations were found be-
tween the underlying structure of cellular networks and disease 
comorbidity patterns. This study suggests that a combination of 
population-level data and cellular network information could help 
build novel hypotheses about disease mechanisms. Complementary 
approaches using computational models extended from existing 
models derived from the Physiome project [115] and statistical 
modelling can be used to further define phenotypes and develop 
predictive models within the framework of a fully integrated 
knowledge management systems [116].  
Systems Biology to Identify Unbiased Novel Biomarkers and 
Mechanisms 
 Medical informatics play a key role to structure, integrate and 
provide access to the enormous amount of data generated [15]. 
Modelling biological systems is one of the most challenging and 
fastest growing research areas in applied mathematics and physics 
which are used with support of computer sciences and infrastruc-
tures to describe biology at different levels: genes, proteins, cells 
and populations. As an example, stochastic modelling may be used 
since it is suited to cell biology [117] and immunology [118] at 
many scales of biodiversity impact. In addition, non-parametric 
modelling of the temporal behaviour of disease read-outs at short 
[78] or long time [77] intervals has shown to be successful in iden-
tifying NCDs and their sub-phenotypes. It is however of paramount 
importance to perform system biology approaches on precisely 
defined clinically phenotyped subjects. 
 The development of biomarkers is a bottleneck in the discovery 
and development of new medicines as identified by the Innovative 
Medicines Initiative (IMI). In most NCDs, finding a single bio-
marker is probably insufficient and a panel of biomarkers is re-
quired. Biomakers improve the understanding of molecular mecha-
nisms of diseases, identify possible new disease pathways, predict 
models of complex diseases, determine the level of biological activ-
ity of the disease, refine disease phenotypes and guide treatment 
responses, and possibly lead to personalised medicine. 
 Novel phenotypes of co-morbidities and NCD complexity can 
be defined and further tested using iterative cycles of modelling and 
experimental testing (Fig. 8). Attempts to find unbiased novel bio-
markers of disease development, severity, activity, control, progres-
sion and prognosis by combining clinical data with genomics, epi-
genetics, proteomics, transcriptomics, metagenomics and me-
tabolomics, integrated in a systems biology approach are of great 
potential. Data analysis, integration and modelling require strict 
statistical procedures in order to avoid false discoveries [119]. 
Some of these methods are currently used to assess the mechanisms 
of the development of allergy (MeDALL [16, 120]). Such an ap-
proach may be used to model NCDs [121]. These biomarkers need 
to be validated and replicated in independent case control or pro-
spective patient cohort studies [122, 123]. Based on studies in non-
medical complex ecosystems, “early warning signals” that predict 
the state of disease progression and the occurrence of abrupt phase 
transitions may be found [124]. 
 Functional genomics and systems biology approaches in pe-
ripheral blood, fluid samples or tissues will generate NCD pheno-
types extending knowledge on key mechanisms of NCD co-
morbidities, and identify and validate novel network perturbations. 
The MeDALL Approach for Allergic Diseases 
 The origin of the epidemic of IgE-associated (allergic) diseases 
is unclear. The project “Mechanisms of the Development of AL-
Lergy (MeDALL)” [16], an FP7 project, aims to generate novel 
knowledge on the mechanisms of initiation of allergy and to pro-
pose early diagnosis, prevention, and targets for therapy. A novel 
phenotype definition and an integrative translational approach are 
needed to understand how a network of molecular and environ-
mental factors can lead to complex allergic diseases.  
 MeDALL proposes a novel, stepwise, large-scale and integra-
tive approach leaded by experts in allergy, epidemiology, allergen 
biochemistry, immunology, molecular biology, epigenetics and 
genomics, functional genomics, bioinformatics, computational and 
systems biology, combining the strengths of previous and ongoing 
EU projects. A feasible and achievable project links epidemiologi-
cal and clinical research with experimental and animal models. 
 MeDALL follows the following strategy: 
1. Definition of classical and novel phenotypes of IgE-
associated allergic diseases: Single phenotypes like asthma, 
rhinitis and atopic dermatitis are complex and heterogeneous. 
Clustering of single phenotypes in subjects and populations is 
not yet understood. Classical (expert based) and novel pheno-
types (obtained by hypothesis free statistical models using la-
tent class and cluster analysis) in existing birth cohorts will be 
compared [120]. The novel phenotypes will be extensively 
characterised by running IgE and IgG arrays in 2,000 existing 
samples of birth cohorts. This will also make it possible to 
 
Fig. (7). Integrated care for NCDs. 
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characterize potential inhalant and food allergens across 
Europe. 
2. Building discovery using cross-sectional analysis of Kare-
lian children [125, 126] and European birth cohorts. These 
studies will be carried out on children with IgE-associated dis-
eases, asthma, atopic dermatitis and food allergy. They will 
capitalise on existing and expanding clinical tests, information 
on health, disease and exposures, biobanks from longitudinal 
population studies (birth cohorts and Karelia cross-sectional 
studies). Pooled databases will include all children from the 
birth cohorts on allergic diseases, environmental exposures, 
outcomes, biomarkers and genes. 
3. Building discovery using longitudinal analysis in European 
birth cohorts. Within MeDALL, several European birth co-
horts on asthma and allergy which previously collaborated in 
GALEN [127, 128] and ENRIECO [129] are performing a 
harmonized follow-up assessment with identical question-
naires and clinical methods. Their study participants will be in 
preschool and early school-age (4-10 years) and in adoles-
cence (14-18 years). Previously collected (historical) data and 
new follow-up data using a harmonized questionnaire will be 
included in a common database in order to perform pooled 
pan-European data analyses. The primary aims of these analy-
ses will be the examination of early childhood predictors for 
allergy and asthma later in life as well as gender differences in 
the natural course of the disease. Unsupervised statistical 
analysis will be carried out to compare novel phenotypes 
(data-driven) to classical phenotypes (hypothesis-driven) 
[120]. These cross-sectional and longitudinal studies will make 
it feasible: 
• To use a large number of possibilities for experimental studies: 
epigenetics (DNA samples) [130], expression profiling 
(mRNA), systems biology, IgE and IgG4 serology (component 
resolved diagnosis), serum biomarkers.  
• To analyse the data for environmental protection/susceptibility 
factors in both the classical and the novel phenotypes taking 
into account a wide range of mechanistic data. 
4. Classical approach for phenotype definition and predictive 
biomarkers  
• The classical phenotypes will be sampled according to both 
informative and power criteria. 
• Blood samples will be tested against a large range of biomark-
ers to obtain a limited range of candidate biomarkers.  
• The predictive validity of biomarkers will then be assessed on 
the new phenotypic information provided by the birth cohorts 
follow-up.  
5. Novel approach for phenotype definition and predictive 
biomarkers  
• From the existing data of birth cohorts, novel phenotypes will 
be segregated through appropriate statistical modelling. 
• Targeted proteomics, transcriptomics, and epigenetics will be 
performed in groups of samples to determine candidate bio-
markers (novel fingerprints). In a further step, the results of the 
latter assays will be integrated by mathematical modelling into 
novel phenotypes handprints.  
• Fingerprints and phenotype handprints will be extensively 
validated in birth cohorts. Systems biology will be carried out 
on nested case samples of these cohorts to characterize bio-
markers. A stepwise approach will be proposed. Fingerprints 
of clinical data, IgE, epigenetics, targeted proteomics and tran-
scriptomics data will be identified in order to select some ex-
pected and novel pathways. These will be further studied in a 
larger number of samples from birth cohorts (confirmation in 
samples already available and replication on samples obtained 
in the follow up study). Finally, all fingerprints will be com-
bined into phenotype handprints to identify biomarkers. 
• Confirmatory studies in SCID (severe combined immunodefi-
ciency (severe combined immunodeficiency) mouse and other 
animal models will be used to confirm novel phenotypes. 
• In vitro human studies will be used to investigate the effect of 
environment on T and B regulatory and effector cells. 
 
Fig. (8). Workflow of systems biology for NCDs (from Bousquet et al [17]). 
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• In the novel approach, iterative improvement of mathematical 
modelling will be used. 
The Following Studies have been Completed 
• Definitions of the classical phenotypes of allergic diseases 
were based on an initial literature review and agreed upon by 
experts in a MeDALL meeting organized in June 2011. A pro-
tocol for the review of classical phenotypes was drafted and an 
initial literature mining has been performed including 219 
original studies and 129 ad-hoc studies. This protocol can be 
applicable to systematic reviews for other complex and convo-
luted chronic diseases. 
• A harmonized questionnaire for prospective birth cohorts has 
been designed and is available as a web-based version in 4 
languages. This questionnaire allows the comparison of pro-
spective data across all participating birth cohorts. 
• A pooled database of recent ongoing longitudinal birth cohorts 
on allergy-related phenotypes (atopic dermatitis, rhinitis and 
asthma) has been built. It is using historical data from the 14 
birth cohorts participating in MeDALL, which are spread 
across Europe, making this study unique in terms of geo-
graphical variability. The data of over 44,000 children have 
been included: 22,417 aged around 4-6 years and 18,975 aged 
around 8-10 years.  
• Based on the pooled database, the prevalence of the classical 
phenotypes of allergic diseases using the MeDALL-agreed 
definitions was analysed per age period (4-6 year, 8-10 year) 
in the pooled data and also per cohort, and according to avail-
ability of specific antibodies against allergens in serum sam-
ples.  
8. NOVEL HEALTH CARE SYSTEM BASED ON NCD CO-
MORBIDITIES 
 Integrated care for NCD co-morbidities should not only include 
the phenotypic characterisation of the patients using clinical and 
biologic methods but shoud integrate all components of health care 
including patient’s views, health and social care and all 
stakeholders involved in the process. 
Patient Empowerment 
 The patient should be at the centre of the system using an opti-
mal multidisciplinary approach when needed. Any study should be 
built around carefully phenotyped patients and follow high meth-
odological standards. A challenge will be to develop automated and 
integrated workflows that predict the most suitable therapeutic 
strategy not only at the population level but for an individual pa-
tient. Patients should be involved during the entire cycle of deci-
sions for an integrated care programme. The goal and rationale of 
patient involvement in medical decisions is patient empowerment. 
Empowered patient knows their disease, have the skills and motiva-
tion to take good care in their everyday life, adjust treatment and be 
prepared in new or potentially exacerbating situations, detect side-
effects, take contact with healthcare professional when needed and 
adhere to treatment regime. Many tools support empowerment, 
shared decision making models and patient education. Patient 
empowerment should be included in healthcare professionals’ cur-
riculum. International guidelines in allergy and asthma recognize 
the need for patient involvement and empowerment. Another key 
aspect of patient involvement in medical decisions is the patient 
representatives’ involvement in the healthcare policy and organiza-
tion in practice [131]. Among the many questions, 3 could be care-
fully evaluated:  
• Acceptance of NCDs by the patient. 
• Engagement of patients in decisions regarding management 
[132], research and clinical trials [61]. 
• Improvement of quality-of-life with the proposed manage-
ment. 
Political Commitment Closing the Gaps in Public Health Issues 
 A leading priority of the  European Union is to reduce health 
inequalities across European societies, and, within its framework to 
improve prevention and control of NCDs, in particular in the eld-
erly. A strong political commitment has been achieved by the EIP 
on AHA. It is vital for the deployment and implementation of suc-
cessful integrated care programmes for NCDs.  
Population Health Science Leading to a Novel Health Care Sys-
tem for Patients with NCDs 
 There is a need for population health sciences to integrate per-
sonalized medicine in public health interventions in order to prevent 
and manage NCDs in a cost-effective manner. Support for this ap-
proach is for example an important element of the UK Medical 
Research Council strategy “Research Changing Lives” 
(http://www.mrc.ac.uk/ StrategicPlan2009-2014).  
 NCDs can disconnect populations from their usual milieu, with 
negative implications for physical and mental well-being. In the 
social domain, there is mounting evidence that those who have 
fewer resources are more vulnerable to NCDs. It is vital for the 
success of policies that they distribute the burdens equitably and 
that impacts on jobs and on the life of underserved groups are taken 
into account. The social dimension of the consequences of NCDs 
needs to be pursued in the social and employment fields, and all 
social partners need to be involved. Issues like gender and age need 
to be integrated into the systems based decision paths for preven-
tion and therapy. 
 Moving beyond the disease-by-disease approach to tackle 
NCDs overall demands a better understanding of their common 
causes. The common causes are more likely to be upstream social 
and environmental factors rather than specific individual exposures. 
Research should be oriented to identify these determinants and to 
develop effective actions. The 2008 WHO Commission on Social 
Determinants of Health recently urged that gaps in health due to 
political social and economic factors be closed in a generation 
[133]. Achieving this goal requires a social determinants approach 
to create public health systems that translate efficacy documented 
by research into effectiveness in the community [134].  
 In order to understand, preserve and improve the health of hu-
man populations and individuals, an integrated proposal could in-
clude: 
Medico-Economic Studies Assessing Cost-Effectiveness  
 Direct and indirect costs incurred by uncontrolled NCDs are 
substantial for the patient, the family and the society, especially in 
undeserved population [135]. P4 medicine should be put in the 
context of health economics to show that expensive strategies are 
cost-effective [61]. 
Micro and Macro-Economic Perspectives 
 NCDs place a considerable economic burden on the society and 
increase inequities. People who have fewer resources are more 
vulnerable. The social dimension of NCDs to be pursued in the 
economic and employment fields, and all stakeholders need to be 
involved. The net social benefit of improving medical and social 
care related to NCDs should take co-benefits into account.  
 Health costs for NCDs should be balanced with health benefits, 
wealth creation and economic development.  
 The management of NCDs involves the necessary coordination 
of stakeholders in the public and private sectors within a govern-
ance framework that includes networks of care.  
Systems Medicine in Chronic Diseases and Ageing Current Pharmaceutical Design, 2014, Vol. 20, No. 00    13 
Development of Guidelines and Policies 
 Using data obtained from all components of research, guide-
lines on NCDs applicable to primary care could be developed using 
up-to-date methodology [136]. A major problem of current guide-
lines is that they focus only on one disease. Yet, co-morbidity is a 
key problem for basically all NCDs and management of a single 
disease in the context of some others may be difficult, may require 
a different approach/understanding and certainly has the potential to 
harm [137]. Then, policies for implementation could be proposed to 
translate the concept and management of NCDs into practice. 
Adherence to Interventions and Health Literacy 
 Guidelines should be implemented and applied by physicians 
and patients. Patient-centredness is a core component of cost-
effective high-quality care [138]. Non-adherence is accompanied 
with increased impaired health outcomes, services utilisation and 
costs. The ABC FP7 project [95] developed strategies for policy-
makers to change the behaviour of patients and healthcare profes-
sionals, in order to enhance patient adherence. One specific issue in 
co-morbidities is poly-pharmacy, which is related to low adherence 
and medication safety. Well-informed patients can make more in-
formed choices and decisions, leading to earlier diagnosis and re-
covery. Conversely, low health literacy is associated with poorer 
health outcomes and poorer use of health care services [139]. 
Health literacy interventions are cost-effective in increasing adher-
ence. Within a holistic, multi-morbidity approach it would be sensi-
ble to include non-medication “prescriptions” such as those for 
lifestyle advice – since adherence to lifestyle advice is even lower 
than to medications. 
Links with the Industry Through SMEs and Large Enterprises 
 One key mission of any integrated care programme for NCDs 
will be to ensure the successful transfer of innovation to the private 
sector. A business plan should actively seek patent protection and 
encourage the negotiation of licensing agreements aimed at bring-
ing the most promising technologies to market and to the patient's 
bedside, also taking into account justice issues.  
 SMEs and large enterprises (pharmaceutical industry, ICT, 
others) should participate to provide technical grounds on which 
novel knowledge is generated and rapidly transformed in market-
grade products to fulfil the needs of the EIP on AHA for the benefit 
of patients.  
 On 26 May 2012, the World Health Assembly adopted a resolu-
tion that could mark the beginning of a needed change in the cur-
rent model of pharmaceutical R&D (Research and Development), 
and may lead to a novel global research and development agree-
ment [140]. If this model is implemented in the future it twill be of 
paramount importance to align research for NCDs with the recom-
mendations.  
Embedding Public Health Actions in Ethical Frameworks 
 Strategies that consider NCDs in their totality with a focus on 
co-morbidities to improve the efficacy of care delivered to patients, 
can offer an efficient use of health service resources [141]. These 
organisational aspects include an essential ethical dimension of 
health care. 
 Values are at the basis of most actions in health sectors as well 
as of economic models. However they often are not made explicit. 
Changing paradigms and approaches for NCDs may challenge fun-
damental societal values and professional habits [142, 143]. With 
the multiplication of active stakeholders, their respective weight in 
the priority setting must be made clear. Transparency and propor-
tionality may be prominent key features. Governance systems are 
key elements to set up in order to assure an optimal translation of 
modern biology into health applications while considering as well 
their societal dimension in a world where ethical values are strongly 
culturally embedded.  
Training  
 Training is an essential component to educate all stakeholders 
on the approach, research and management of patients with NCDs 
using innovative training programmes (e.g. ICT).  
 Moreover, all stakeholders could have the right to be educated 
in a transversal manner to better understand NCDs in their totality. 
Education will address the question of how to teach and how people 
learn. Rather than seeing education as a process of transmission and 
transaction, training will include frames of reference for everyone 
involved in the combat against NCDs. This includes points of view, 
habits of mind, and all the information requested for the needs of 
the strategy. This programme needs to carry out educational ecosys-
tems to help participants think differently about NCDs. A module 
of this programme should be developed with patients to help them 
engaging in all aspects of NCDs including research.  
 Working in interdisciplinary teams is a challenge in itself which 
needs to be in future training initiatives, otherwise the success of 
the programme is endangered. 
9. IMPACT ON POLICIES 
Reduction of Inequalities (Including Gender)  
 One particular concern is that NCD patients with low socioeco-
nomic status bear a disproportionate burden of diseases. The Euro-
pean Commission has addressed NCDs a key priority from different 
angles. There is a specific policy focus on reducing health inequali-
ties in NCDs through the 2009 European Commission Communica-
tion on reducing health inequalities in the EU (20 October 2009, 
http://ec.europa.eu/health). These policies tie in with active Com-
mission support for the current United Nations Process to address 
NCDs and related socio-economic and environmental determinants. 
Even in the high- and middle-income countries of Europe, the pos-
sibilities for surviving and living a healthy life are still closely re-
lated to the socioeconomic background of individuals and families. 
These are reflected in substantial and even increasing social inequi-
ties in health within countries across Europe. These health inequi-
ties are unfair and avoidable, as they are caused by unhealthy public 
policies and lifestyles.  
 Equality between women and men is a fundamental right and a 
common principle of the EU. The EU can be considered as one of 
the main actors in this field. Since the 1970s, the EU has adopted an 
extensive body of equal treatment legislation and 13 directives ad-
dressing this domain. However, understanding gender differences in 
complex chronic disease phenotypes will help the European Com-
mission's commitment to gender equality outlined in the Roadmap 
for equality between women and men 2006-2010 with the adoption 
of a follow-up strategy. 
European Innovation Partnership on Active and Healthy Age-
ing 
 Ageing raises important challenges for the 21st century: meet 
the higher demand for healthcare; adapt health systems to the needs 
of an ageing population while keeping them sustainable in societies 
with smaller workforce. Targeting NCDs, their co-morbidities, risk 
factors and socio-economic determinants will have a direct effect 
on healthy ageing by early diagnosis, prevention and treatment of 
hidden co-morbidities to increase healthy life years and reduce 
hospitalisations.  
 The objective of EIP on AHA is to foster innovation in prod-
ucts, processes and services, and in parallel facilitate the innovation 
chain and reduce the time to market for innovative solutions. Ulti-
mately this will produce benefits for innovation's final users – the 
older people and care providers. 
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Global Fight Against NCDs 
 Most patients with NCDs live in developing countries where 
medications and services are often unavailable or inaccessible. Not 
only effective medications should be available for all patients such 
as inhaled corticosteroids for asthma [144] or insulin for diabetes 
[145], but there should be a global cost-effective application of P4 
medicine in the world. Genomics are now widely used in develop-
ing countries and ICT will rapidly become available to many devel-
oping countries at a relatively cheap expenditure. 
 In addition, new private-public strategic partnerships, such as 
the pre-competitive Innovative Medicines Initiative, a joint under-
taking of the European Union and the European Federation of 
Pharmaceutical Industry Associations (www.imi.europa.eu), and 
the Program on Public-Private Partnerships of the United States 
National Institutes of Health Roadmap [http://nihroadmap.nih.gov/] 
are required to overcome the bottlenecks towards the development 
of novel treatment strategies [146].  
 WHO actively supports capacity building, especially in devel-
oping countries, fosters partnerships around the world, and works to 
narrow the gap in healthcare inequities through the access of inno-
vative approaches taking into account different health systems, 
economic and cultural aspects. Despite the growing consensus for 
the need for health system strengthening, there is little agreement 
on strategies for its implementation [147]. Widely accepted guiding 
principles should be developed with a common language for strat-
egy development and communication in the global community in 
general [148] and in NCDs in particular. 
CONCLUSIONS 
 The novel trend for the management of NCDs is evolving to-
wards integrative, holistic approaches. To tackle them globally and 
in their totality in order to reduce their burden and societal impact, 
it is proposed that NCDs could be considered as a single expression 
of disease with different risk factors and entities.  
 P4 medicine for NCDs can have a strong societal impact and, 
ultimately, could lead to reduction of inequities around the world. 
Expected results include the structuring of translational research in 
a global approach of chronic disease, the development of preven-
tion and treatment, a better support for patients through the elabora-
tion of health care systems and follow up at home in improved con-
ditions, a slowing down of the increase in health expenditure, a 
contribution to novel training courses for new skills and the appli-
cation of this novel knowledge to all people in the world. 
 Integrated care for NCD patients, in particular the elderly will 
reduce inequities while boosting the economy of all countries in the 
world. 
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